Your session is about to expire
← Back to Search
Multilevel Connection Tool for Cancer Patients
N/A
Waitlist Available
Led By Janice Krieger, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within two months of consent
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a tool to help Black and Hispanic cancer patients & families get referrals to cancer treatment centers.
Who is the study for?
This trial is for Black and Hispanic adults aged 18 to 73 in Florida, who can read English or Spanish at an eighth-grade level, are willing to be re-contacted, and have email or text capabilities. It's aimed at those underrepresented in cancer clinical trials.
What is being tested?
The study tests a tailored ALEX Research Portal with a virtual Community Health Educator against a stand-alone portal to help guide these populations through referrals to cancer clinical trials.
What are the potential side effects?
Since this trial involves the use of informational portals rather than medical interventions, there are no direct physical side effects associated with participating.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ within 2 months of consent
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 2 months of consent
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of patients who self-refer to cancer clinical trials
Secondary study objectives
Change in trust in Cancer Clinical Trials
Mediators of intervention effectiveness
Virtual Clinical Health Education (vCHE) preferences
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Stand-alone PortalExperimental Treatment1 Intervention
The standard of care condition will include a portal that provides patients with access to existing online cancer clinical trial resources in one location. This includes links to pages with basic information about cancer clinical trials, ongoing studies, enrollment opportunities for existing institutional research registries, and contact information for study coordinators.
Group II: Portal with Virtual Community Health Educator (vCHE)Experimental Treatment1 Intervention
The virtual community health educator condition will provide all information in standard of care with the addition of a virtual community health educator. Patients will have the opportunity to choose which virtual community health educator will provide digital navigation. The choices will include at least four English-speaking and four Spanish-speaking virtual community health educators representing different genders and racial/ethnic backgrounds.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,324 Previous Clinical Trials
3,059,055 Total Patients Enrolled
University of FloridaLead Sponsor
1,393 Previous Clinical Trials
766,674 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,906 Previous Clinical Trials
41,011,682 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 18 and 100 years old.I can receive emails or texts.
Research Study Groups:
This trial has the following groups:- Group 1: Stand-alone Portal
- Group 2: Portal with Virtual Community Health Educator (vCHE)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger